Because of this, the reverse of any number that is divisible by three (or indeed, any permutation of its digits) is also divisible by three. For instance, 1368 and its reverse 8631 are both divisible by three (and so are 1386, 3168, 3186, 3618, etc.). See also Divisibility rule. This works in base 10 and in any positional numeral system whose base divided by three leaves a remainder of one (bases 4, 7, 10, etc.). Three of the five Platonic solids have triangular faces – the tetrahedron, the octahedron, and the icosahedron. Also, three of the five Platonic solids have vertices where three faces meet – the tetrahedron, the hexahedron (cube), and the dodecahedron. Furthermore, only three different types of polygons comprise the faces of the five Platonic solids – the triangle, the square, and the pentagon. There are only three distinct 4×4 panmagic squares. According to Pythagoras and the Pythagorean school, the number 3, which they called triad, is the noblest of all digits, as it is the only number to equal the sum of all the terms below it, and the only number whose sum with those below equals the product of them and itself.There are three finite convex uniform polytope groups in three dimensions, aside from the infinite families of prisms and antiprisms: the tetrahedral group, the octahedral group, and the icosahedral group.
In the longest, largest phase 3 trial, patients in the Lunesta group reported falling asleep an average of 15 minutes faster and sleeping an average of 37 minutes longer than those in the placebo group. However, on average, Lunesta patients still met criteria for insomnia and reported no clinically meaningful improvement in next-day alertness or functioning." Availability in Europe
On September 11, 2007, Sepracor signed a marketing deal with British pharmaceutical company GlaxoSmithKline for the rights to sell eszopiclone (under the name Lunivia rather than Lunesta) in Europe. Sepracor was expected to receive approximately $155 million if the deal went through. In 2008 Sepracor submitted an application to the EMA (the European Unions equivalent to the U.S. FDA) for authorization to market the drug in the EU, and initially received a favorable response. However, Sepracor withdrew its authorization application in 2009 after the EMA stated it would not be granting eszopiclone new active substance status, as it was essentially pharmacologically and therapeutically too similar to zopiclone to be considered a new patentable product. Since the patent on zopiclone has expired, this ruling would have allowed rival companies to also legally produce cheaper generic versions of eszopiclone for the European market. As of November 2012, Sepracor has not resubmitted its authorization application and eszopiclone is not available in Europe. The deal with GSK fell through, and GSK instead launched a $3.3 billion deal to market Actelions almorexant sleeping tablet, which entered phase 3 medical trials before development was abandoned due to side effects. References
External links
"Eszopiclone". Drug Information Portal.